Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34
Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22
Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17
Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds
Loading...